Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Last Updated on: 04 March, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of Sequent Scientific Ltd

About the Company - Sequent Scientific Ltd

Sequent Scientific Ltd. is a Public Limited Listed company incorporated on 28/06/1985 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L99999MH1985PLC036685 and registration number is 036685. Currently Company is involved in the business activities of Manufacture of veterinary preparations. Company’s Total Operating Revenue is Rs. 219.63 Cr. and Equity Capital is Rs. 49.67 Cr. for the Year ended 31/03/2022.
Pharmaceuticals301, 3rd Floor, �Dosti Pinnacle�, Plot No. E7, Road No.22, Mumbai Maharashtra
NamePosition Held
Dr. Kamal K SharmaChairman & Ind.Director
Mr. Rajaram NarayananManaging Director & CEO
Mr. Sharat NarasapurJoint Managing Director
Mr. Gregory John AndrewsNon Executive Director
Mr. Neeraj BharadwajNon Executive Director
Dr. Fabian KauscheNon Executive Director
Dr.(Mrs.) Kausalya SanthanamIndependent Director
Mr. Milind SarwateIndependent Director

Sequent Scientific Ltd. Share Price Update

Share PriceValue
Previous Day₹132.35

Basic Stock Data of Sequent Scientific Ltd

Market Cap 3,335 Cr.
Current Price 134
High / Low156/61.8
Stock P/E
Book Value 25.3
Dividend Yield0.00 %
ROCE3.43 %
ROE8.98 %
Face Value 2.00

Data Source:

Competitors of Sequent Scientific Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Wockhardt Ltd 8,549 Cr. 593630/145 2170.00 %0.46 %8.31 % 5.00
Panacea Biotec Ltd 952 Cr. 155202/107 1380.00 %10.3 %10.9 % 1.00
IOL Chemicals & Pharmaceuticals Ltd 2,452 Cr. 418536/27214.2 2711.20 %13.7 %9.68 % 10.0
Adline Chem Lab Ltd 16.8 Cr. 28.729.0/5.15 2.870.00 %5.90 %22.2 % 10.0
Venus Remedies Ltd 451 Cr. 338430/15115.5 3520.00 %7.75 %5.90 % 10.0
Industry Average2,484.16 Cr306.545.94196.170.24%7.62%11.40%7.20

Sequent Scientific Ltd Quarterly Results

MonthSep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Operating Profit58.7964.5243.2820.1519.6736.2233.352.122.8710.35-3.37-8.2415.13
OPM %16.82%18.17%11.96%6.29%5.61%10.12%8.69%0.62%0.85%2.76%-0.92%-2.47%4.37%
Other Income-6.402.811.592.670.743.673.77-2.320.912.86-59.86-22.729.72
Profit before tax31.7349.5429.017.233.9423.6118.15-20.93-17.72-10.19-88.81-55.68-3.09
Tax %25.59%23.33%18.89%63.35%-250.51%21.39%45.45%26.85%74.94%4.12%-4.10%37.72%-122.65%
Net Profit23.5937.9823.522.6513.8218.569.90-15.32-4.44-9.78-92.43-34.68-6.88
EPS in Rs0.951.430.830.040.580.690.36-0.60-0.15-0.36-3.75-1.40-0.34

Sequent Scientific Ltd Quarterly Chart

Sequent Scientific Ltd Profit & Loss

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Operating Profit37-136185643831251702121091214
OPM %11%-4%2%4%9%6%10%12%14%16%8%1%1%
Other Income103-5448149436910-011-58-70
Profit before tax-5-73-110-8-14-17444599413753-138-158
Tax %73%11%-1%-40%-19%3%3%3%13%24%15%11%
Net Profit-1-65-110-12-16-16431578210445-122-144
EPS in Rs-0.13-5.39-8.09-0.70-0.78-0.5717.301.972.813.841.65-4.86-5.85
Dividend Payout %0%0%0%0%0%0%1%10%0%13%0%0%

Sequent Scientific Ltd Profit & Loss Yearly Chart

Sequent Scientific Ltd Growth

Compounded Sales Growth
10 Years:16%
5 Years:11%
3 Years:6%
Compounded Profit Growth
10 Years:0%
5 Years:%
3 Years:%
Stock Price CAGR
10 Years:14%
5 Years:13%
3 Years:-18%
1 Year:113%
Return on Equity
10 Years:9%
5 Years:6%
3 Years:4%
Last Year:-9%

Sequent Scientific Ltd Balance Sheet

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital21232730484949495050505050
Other Liabilities156192159372278503380346424381378374408
Total Liabilities5475866239081,5231,8961,3321,3781,4541,3861,4351,5171,501
Fixed Assets230227238474586684476498577536564605592
Other Assets253268342336485751599677693737821856872
Total Assets5475866239081,5231,8961,3321,3781,4541,3861,4351,5171,501

Sequent Scientific Ltd Reserves and Borrowings Chart

Torrent Pharmaceuticals Ltd Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 21-4-45-24-0-7451161151153117
Cash from Investing Activity -65-55-81-157-310-1167-68-7210-94-65
Cash from Financing Activity 6235146179309147-57-20-43-1396732
Net Cash Flow18-2420-1-224-5280-144-16

Sequent Scientific Ltd Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days747377951161361119899938588
Inventory Days130173175153164165125134132139160152
Days Payable236306198147175208127141133119119107
Cash Conversion Cycle-32-5954101105931109298112126132
Working Capital Days-3454757997986777488106115
ROCE %5%-10%-4%9%2%1%40%9%12%16%6%-3%

Sequent Scientific Ltd Financial Efficiency Indicators Chart

Sequent Scientific Ltd Share Holding Pattern

MonthMar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
No. of Shareholders62,31886,8481,24,0141,67,8121,91,0921,97,1761,93,9541,96,2311,91,8751,87,4741,84,5211,72,853

Sequent Scientific Ltd Shareholding Pattern Chart

No. of Sequent Scientific Ltd Shareholders

Sequent Scientific Ltd Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)
Quant Small Cap Fund107889250.94122.72
UTI Healthcare Fund6203050.817.06
Motilal Oswal Nifty Microcap 250 Index Fund1320970.241.5
ITI Pharma and Healthcare Fund1157960.921.32
Motilal Oswal S&P BSE Healthcare ETF12440.150.01

Sequent Scientific Ltd ROCE Trend

Sequent Scientific Ltd EPS Trend

Sequent Scientific Ltd Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
Basic EPS (Rs.)-4.881.673.872.872.00
Diluted EPS (Rs.)-4.881.653.852.851.99
Cash EPS (Rs.)-2.663.876.245.344.00
Book Value[Excl.RevalReserv]/Share (Rs.)30.0429.4431.2631.7130.26
Book Value[Incl.RevalReserv]/Share (Rs.)30.0429.4431.2631.7130.26
Revenue From Operations / Share (Rs.)56.9756.8854.8247.4842.10
PBDIT / Share (Rs.)0.734.848.887.265.41
PBIT / Share (Rs.)-1.502.786.845.233.71
PBT / Share (Rs.)-5.522.155.503.792.39
Net Profit / Share (Rs.)-4.891.814.213.302.30
NP After MI And SOA / Share (Rs.)-4.861.663.842.811.97
PBDIT Margin (%)1.298.5116.1815.2912.85
PBIT Margin (%)-2.624.8912.4711.008.82
PBT Margin (%)-9.683.7710.037.975.66
Net Profit Margin (%)-8.583.187.676.955.47
NP After MI And SOA Margin (%)-8.522.917.005.924.68
Return on Networth / Equity (%)-17.336.0313.119.416.88
Return on Capital Employeed (%)-3.727.4418.2212.379.60
Return On Assets (%)-7.922.866.854.603.50
Long Term Debt / Equity (X)
Total Debt / Equity (X)0.560.460.270.380.37
Asset Turnover Ratio (%)
Current Ratio (X)1.501.541.551.501.38
Quick Ratio (X)0.840.850.971.030.92
Inventory Turnover Ratio (X)0.570.740.870.930.84
Interest Coverage Ratio (X)0.517.629.045.054.07
Interest Coverage Ratio (Post Tax) (X)-0.613.865.653.302.73
Enterprise Value (Cr.)2217.183626.836172.312183.162008.66
EV / Net Operating Revenue (X)1.562.574.531.851.93
EV / EBITDA (X)120.8630.1628.0012.1015.03
MarketCap / Net Operating Revenue (X)1.272.354.391.641.71
Price / BV (X)2.594.868.222.602.51
Price / Net Operating Revenue (X)1.272.354.391.641.71

Sequent Scientific Ltd Profitability Ratios (%)

Sequent Scientific Ltd Liquidity Ratios

Sequent Scientific Ltd Liquidity Ratios (%)

Sequent Scientific Ltd Interest Coverage Ratios (X)

Sequent Scientific Ltd Valuation Ratios

Fair Value / Intrinsic Value of Sequent Scientific Ltd

Fair Value: ₹34.76

The stock is overvalued by 74.06% compared to the current price ₹134

*Investments are subject to market risks

Strength and Weakness of Sequent Scientific Ltd

  1. The company has higher reserves (497.62 cr) compared to borrowings (363.00 cr), indicating strong financial stability.
  2. The company has shown consistent growth in sales (281.15 cr) and profit (20.31 cr) over the years.
  1. The stock is trading at a high valuation with an average P/B ratio of 3.41 and average Dividend Yield of 6.91%.
  2. The stock has a low average ROCE of 6.92%, which may not be favorable.
  3. The stock has a high average Working Capital Days of 66.58, which may not be favorable.
  4. The stock has a high average Cash Conversion Cycle of 77.67, which may not be favorable.

Should I Buy Sequent Scientific Ltd Share Now?

  • Considering various financial indicators, investors might exercise caution regarding investment in Sequent Scientific Ltd:
    1. Net Profit Margin: -8.58%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: -3.72% (Industry Average ROCE: 28.84%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. Interest Coverage Ratio (Post Tax): -0.61
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    4. Quick Ratio: 0.84
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    5. ✓ Stock P/E of N/A (Industry average Stock P/E: 40.46)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    6. ✓ Total Debt / Equity: 0.56
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis suggests exercising caution. It's advisable to conduct further research or consult with financial experts before considering any investment.

About the Author

Author Avatar

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Sequent Scientific Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE